타크로리무스(tacrolimus), 그 염류 및유도체
Listed by the Korean MFDS as a substance that may not be used in cosmetics.
Décision réglementaire et conditions complètes
- Statut
- Prohibited
- Rôle juridique
- Binding rule
- Résumé réglementaire
- Listed by the Korean MFDS as a substance that may not be used in cosmetics.
- Conditions et restrictions
타크로리무스
Identité de la substance
- Nom dans la source officielle
- 타크로리무스(tacrolimus), 그 염류 및유도체
- CAS
- 104987-11-3
- EC
- Not supplied in this source row
- Correspondance d’identité
- standalone:official_korean_name
Aperçu multi-marchés pour cette identité
Fiches exactes associées actuellement présentes sur ce site. L’absence d’un marché signifie qu’aucune correspondance exacte n’a été importée, et non une autorisation d’utiliser la substance.
South Korea
Fiche actuelle1 fiche associée · 1 avec conditions spécifiques
Ouvrir la fiche justificative
Chimie vérifiée pour le CAS 104987-11-3
Tacrolimus
Tacrolimus is a calcineurin inhibitor and potent immunosuppressive agent used largely as a means of prophylaxis against cellular rejection after transplantation. Tacrolimus therapy can be associated with mild serum enzyme elevations, and it has been linked to rare instances of clinically apparent cholestatic liver injury. — LiverTox
- Nom IUPAC
- (1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-[(E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-23,25-dimethoxy-13,19,21,27-tetramethyl-17-prop-2-enyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetrone
- Formule moléculaire
- C44H69NO12
- Masse moléculaire
- 804.0 g/mol
- Masse exacte
- 803.48197664 Da
- Masse monoisotopique
- 803.48197664 Da
- XLogP3
- 2,7
- Surface polaire topologique
- 178,0 Ų
- Complexité moléculaire
- 1480,0
- Charge formelle
- 0
- Donneurs de liaisons hydrogène
- 3
- Accepteurs de liaisons hydrogène
- 12
- Liaisons rotatives
- 7
- Atomes lourds
- 57
- Unités covalentes
- 1
Noms et synonymes signalés à PubChem
16 autres noms signalés
Identifiants de bases de données externes
- ChEBI:CHEBI:61049
- ChEBI:CHEBI:93221
- ChEMBL:CHEMBL269732
- EPA DTXSID:DTXSID5046354
- PubMed:30545944
- PubMed:17965516
- PubMed:16702731
- PubMed:16021174
- PubMed:15896681
- PubMed:14661025
- PubMed:11145792
- PubMed:9857082
- PubMed:2445721
- PubMed:1715244
Statistiques de structure avancées
- Stéréocentres atomiques définis
- 14
- Stéréocentres atomiques non définis
- 0
- Stéréocentres de liaison définis
- 2
- Stéréocentres de liaison non définis
- 0
- Conformères 3D
- 0
Identifiants de structure lisibles par machine
- SMILES
C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC- InChI
InChI=1S/C44H69NO12/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3/b25-19+,27-21+/t26-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39+,40+,44+/m0/s1- InChIKey
QJJXYPPXXYFBGM-LFZNUXCKSA-N
Preuves issues de bases de données scientifiques complémentaires
EMBL-EBI ChEBI
tacrolimus (anhydrous)
A macrolide lactam containing a 23-membered lactone ring, originally isolated from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis.
- Formule
- C44H69NO12
- Masse moyenne
- 804.031 g/mol
- Masse monoisotopique
- 803.48198 Da
- Charge formelle
- 0
- macrolide lactam — is a (CHEBI:145565)
- bacterial metabolite — has role (CHEBI:76969)
- immunosuppressive agent — has role (CHEBI:35705)
- bacterial metabolite — has role (CHEBI:76969)
- immunosuppressive agent — has role (CHEBI:35705)
- macrolide lactam — is a (CHEBI:145565)
Noms supplémentaires validés
Références croisées de cette source
- CAS: 104987-11-3 — KEGG COMPOUND
- CAS: 104987-11-3 — ChemIDplus
- CAS: 104987-11-3 — KEGG DRUG
- REGISTRY_NUMBER: 3647477 — Reaxys
- REGISTRY_NUMBER: 8821611 — Reaxys
- MANUAL_X_REF: C01375 — KEGG COMPOUND
- MANUAL_X_REF: D08556 — KEGG DRUG
- MANUAL_X_REF: DB00864 — DrugBank
- MANUAL_X_REF: EP184162 — Patent
- MANUAL_X_REF: FK5 — PDBeChem
- MANUAL_X_REF: LMPK04000003 — LIPID MAPS
- MANUAL_X_REF: US5665727 — Patent
Mis en correspondance par: Exact CAS cross-reference in the ChEBI compound record. Source mise à jour le: 2019-12-03. Récupéré le: 2026-08-31. Ouvrir la fiche source
NIH PubChem PUG-View
Attributed physical-property, hazard, environmental and use annotations.
- LogP: 3.3 Source: DrugBank
- Melting Point: 126 °C Source: DrugBank
- Solubility: Insoluble Source: DrugBank
- IARC Carcinogenic Agent: Tacrolimus Source: International Agency for Research on Cancer (IARC)
- IARC Carcinogenic Classes: Group 1: Carcinogenic to humans Source: International Agency for Research on Cancer (IARC)
- IARC Monographs: Volume 137: (2026) Hydrochlorothiazide, Voriconazole, and Tacrolimus Source: International Agency for Research on Cancer (IARC)
- Publication Year: 2026 online Source: International Agency for Research on Cancer (IARC)
- Evaluation Year: 2024 Source: International Agency for Research on Cancer (IARC)
- Carcinogen Classification: No indication of carcinogenicity to humans (not listed by IARC). Source: Toxin and Toxin Target Database (T3DB)
- Exposure Routes: Absorption of tacrolimus from the gastrointestinal tract after oral administration is incomplete and variable. The absolute bioavailability in adult kidney transplant patients is 17Њ±10%; in adults liver transplant patients is 22Њ±6%; in healthy subjects is 18Њ±5%. The absolute bioavailability in pediatric liver transplant patients was 31Њ±24%. Tacrolimus maximum blood concentrations (Cmax) and area under the curve (AUC) appeared to increase in a dose-proportional fashion in 18 fasted healthy volunteers receiving a single oral dose of 3, 7, and 10 mg. When given without food, the rate and extent of absorption were the greatest. The time of the meal also affected bioavailability. When given immediately after a meal, mean Cmax was reduced 71%, and mean AUC was reduced 39%, relative to the fasted condition. When administered 1.5 hours following the meal, mean Cmax was reduced 63%, and mean AUC was reduced 39%, relative to the fasted condition. Source: Toxin and Toxin Target Database (T3DB)
- Signal: Danger Source: European Chemicals Agency (ECHA)
- GHS Hazard Statements: H301 (97.6%): Toxic if swallowed [Danger Acute toxicity, oral]; H361 (92.7%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]; H372 (91.5%): Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure] Source: European Chemicals Agency (ECHA)
- Precautionary Statement Codes: P203, P260, P264, P270, P280, P301+P316, P318, P319, P321, P330, P405, and P501 (click each P-code to see the statement) Source: European Chemicals Agency (ECHA)
- ECHA C&L Notifications Summary: Aggregated GHS information provided per 82 reports by companies from 13 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.; Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. Source: European Chemicals Agency (ECHA)
- GHS Hazard Statements: H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]; H361 (100%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]; H372 (100%): Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure] Source: European Chemicals Agency (ECHA)
- ECHA C&L Notifications Summary: The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory. Source: European Chemicals Agency (ECHA)
- Signal: Danger Source: Hazardous Substances Data Bank (HSDB)
- GHS Hazard Statements: H301: Toxic if swallowed [Danger Acute toxicity, oral] Source: Hazardous Substances Data Bank (HSDB)
- Precautionary Statement Codes: P264, P270, P301+P316, P321, P330, P405, and P501 (click each P-code to see the statement) Source: Hazardous Substances Data Bank (HSDB)
- Toxicity Summary: IDENTIFICATION AND USE: Tacrolimus is white to off-white crystalline powder. It is a calcineurin-inhibitor immunosuppressant available in several preparations. Tacrolimus in both oral capsules and a solution for IV injection is used for prophylaxis of organ rejection in patients receiving liver, kidney or heart transplants. Tacrolimus topical ointment is used as a second-line therapy for the short-term and non-continuous chronic treatment of moderate to severe atopic dermatitis in non-immunocompromised adults and children. HUMAN EXPOSURE AND TOXICITY: While most acute overdosages of tacrolimus at up to 30 times the intended dose have been asymptomatic and all patients recovered with no sequelae, some acute overdosages were followed by adverse reactions including tremors, abnormal renal function, hypertension, and peripheral edema. At therapeutic doses, patients receiving tacrolimus are at increased risk of developing lymphomas and other malignancies, particularly of the skin, as well as an increased risk of developing bacterial, viral, fungal, and protozoal infections, including opportunistic infections. These infections may lead to serious, including fatal, outcomes. While there a Source: Hazardous Substances Data Bank (HSDB)
- Toxicity Summary: Signs and Symptoms of Overdose; Tacrolimus toxicity commonly presents as acute kidney injury. Close monitoring of serum creatinine, glomerular filtration rate, and urine output is necessary for patients on tacrolimus. Toxicity may also present as adverse effects, including tremors, electrolyte disturbances, and headaches. Monitor for neurotoxicity, nephrotoxicity, and hypertension. Investigations may indicate increased serum creatinine. An electrocardiogram should be obtained to rule out QT prolongation.; Management of Overdose; No specific antidote is currently available for tacrolimus toxicity, and the drug is not removed by hemodialysis. Management focuses on supportive care, including symptom monitoring and management. Consultation with the poison control center is recommended for current guidance and treatment recommendations. Source: StatPearls
- Toxicity Summary: The mechanism of action of tacrolimus in atopic dermatitis is not known. While the following have been observed, the clinical significance of these observations in atopic dermatitis is not known. It has been demonstrated that tacrolimus inhibits T-lymphocyte activation by first binding to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin is then formed and the phosphatase activity of calcineurin is inhibited. This prevents the dephosphorylation and translocation of nuclear factor of activated T-cells (NF-AT), a nuclear component thought to initiate gene transcription for the formation of lymphokines. Tacrolimus also inhibits the transcription for genes which encode IL-3, IL-4, IL-5, GM-CSF, and TNF-, all of which are involved in the early stages of T-cell activation. Additionally, tacrolimus has been shown to inhibit the release of pre-formed mediators from skin mast cells and basophils, and to downregulate the expression of FceRI on Langerhans cells. Source: Toxin and Toxin Target Database (T3DB)
- Uses: THERAPEUTIC CATEGORY: Immunosupressant; dermatological treatment of atopic eczema Source: Hazardous Substances Data Bank (HSDB)
- Uses: Immunosuppressive Agents Source: Hazardous Substances Data Bank (HSDB)
- Uses: MEDICATION Source: Hazardous Substances Data Bank (HSDB)
- Uses: Use (kg; approx.) in Germany (2009): >25; Use (kg) in USA (2002): 45; Consumption (g per capita; approx.) in Germany (2009): 0.000305; Consumption (g per capita) in the USA (2002): 0.00016; Calculated removal (%): 6 Source: NORMAN Suspect List Exchange
- Uses: For use after allogenic organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It was first approved by the FDA in 1994 for use in liver transplantation, this has been extended to include kidney, heart, small bowel, pancreas, lung, trachea, skin, cornea, and limb transplants. It has also been used in a topical preparation in the treatment of severe atopic dermatitis. Source: Toxin and Toxin Target Database (T3DB)
Mis en correspondance par: Existing checksum-valid CAS to unique PubChem CID match. Récupéré le: 2026-08-31. Ouvrir la fiche source
Les classifications scientifiques et les annotations de danger apportent du contexte et ne remplacent pas la décision réglementaire propre au marché indiquée ci-dessus.
Couverture des sources complémentaires et état des correspondances
| Source | Résultat | Vérifié |
|---|---|---|
| EMBL-EBI ChEBI | Correspondance exacte | 2026-08-31 |
| NIH PubChem PUG-View | Correspondance exacte | 2026-08-31 |
Une absence de correspondance enregistrée est une preuve utile que la source a été vérifiée ; ce n’est pas l’affirmation que la substance n’existe pas ailleurs.
Récupéré depuis NIH PubChem le 2026-08-31 par correspondance CAS à somme de contrôle valide. Les propriétés chimiques ne remplacent pas la décision réglementaire de cette page.
Source officielle et provenance
- Source enregistrée
- South Korea MFDS cosmetic ingredient data
- Référence de la source
- 화장품 안전기준 등에 관한 규정, 별표 1, record 1-946
- Identifiant de la fiche source
1-946- Version de la source
- 2026-19
- Langue de la source
- Korean
- État de la traduction
- No English translation
- Date d’effet
- 2026-03-18
- Source mise à jour le
- 2026-03-18
- Instantané vérifié le
- 2026-08-30 04:33 UTC
- Méthode de validation
- MFDS JSON appendices 1–2 parse; 1077 prohibited, 243 restricted
- SHA-256
056de35b843a5e31f709073f9e79d5e6e18f7c9164eb537bb099b185a37ef7d8
Notes du jeu de données enregistré
- Couverture du jeu de données
- Ingredient identity and separate restriction/regulation data endpoints
- Note sur l’autorité
- Korean source is canonical; English materials alone are not complete enough for certification
Place de cette fiche dans le jeu de données du marché
Répartition des statuts
Un texte de conditions est présent pour 638 des 1320 fiches actuelles. Un champ de conditions vide est interprété selon le type de fiche ci-dessus ; il n’est jamais converti en une affirmation d’utilisation sans restriction.
South Korea contexte du marché
Complete current appendix dataset
Version de la couverture : MFDS Notice 2026-19, effective 18 March 2026
All rows in official Appendix 1 (prohibited) and Appendix 2 (restricted) of the Safety Standards for Cosmetics.
Liste de contrôle de vérification
- Match the Korean canonical substance name and identifiers.
- Review all Appendix 1 and 2 matches and conditions.
- Check functional-cosmetic and positive-list requirements where applicable.
- Confirm current MFDS notice, responsible seller and label obligations.
Sources officielles du marché
- South Korea MFDS cosmetic ingredient dataKorean source is canonical; English materials alone are not complete enough for certification
Procédure de vérification et exhaustivité de la fiche
Avant d’utiliser ce résultat dans une décision de conformité
- Confirmez que « 타크로리무스(tacrolimus), 그 염류 및유도체 » et chaque identifiant CAS/CE correspondent à la matière de votre spécification fournisseur.
- Match the Korean canonical substance name and identifiers.
- Review all Appendix 1 and 2 matches and conditions.
- Check functional-cosmetic and positive-list requirements where applicable.
- Confirm current MFDS notice, responsible seller and label obligations.
- Consignez la version de la source et revérifiez auprès de l’autorité de réglementation avant la fabrication, la notification ou la mise sur le marché.
Champs disponibles dans cette fiche
- Nom officiel de la substanceDisponible
- CASDisponible
- ECNon fourni
- Texte de condition distinctDisponible
- Date d’effetDisponible
- Empreinte de l’instantané et méthodeDisponible
Questions auxquelles cette page répond
Citation stable
타크로리무스(tacrolimus), 그 염류 및유도체. 화장품 안전기준 등에 관한 규정, 별표 1, record 1-946. South Korea. Source version 2026-19. CosIng Checker regulatory record: https://cosingchecker.com/fr/regulations/kr/records/1595/
Citez l’autorité de réglementation comme autorité juridique. Cette page est un index structuré de preuves et une aide à la vérification, et non un substitut au texte officiel ni à une évaluation juridique professionnelle.
Interprétation et limites pour South Korea
This official record identifies the substance as prohibited for cosmetic use in the stated market scope.
Do not rely on a formulation containing this identity until the cited source, effective date and exact substance match have been verified.
Comment interpréter le rôle juridique
The cited row forms part of a binding rule or legally incorporated list for this market.
Preuves sur cette page
- Résultat enregistré : Prohibited
- Rôle juridique : Binding rule
- Version de la source : 2026-19
- Date d’effet : 2026-03-18
Ce que cela ne prouve pas
Korean source wording is canonical and other positive lists/notices may still apply to the formulation.
Recherche complémentaire sur la substance auprès de sources faisant autorité
Aucune de ces sources ne prévaut sur la décision de marché ci-dessus.
Cosmetic Ingredient Review safety assessments
Expert Panel conclusions, assessed ingredient groups, use conditions, dates and report documents
Independent expert review considered by FDA; not a government approval or binding market rule
Rechercher cette identité à la sourceFDA Global Substance Registration System
UNII identifiers, preferred names, substance types, codes and public substance relationships
Identity registry only; UNII availability does not imply FDA review or approval
Rechercher cette identité à la sourceILO/WHO International Chemical Safety Cards
Hazards, symptoms, first aid, storage, incompatibilities and physical properties for covered chemicals
International occupational chemical-safety reference; not cosmetic-use approval
Rechercher cette identité à la sourceJapan NITE-CHRIP
Chemical identity, Japanese and foreign legal lists, GHS hazards and exposure-related information
Chemical-management evidence; cosmetic status remains governed by the applicable MHLW standard and market rules
Rechercher cette identité à la sourceNIOSH Pocket Guide to Chemical Hazards
REL, PEL, IDLH, properties, exposure routes, symptoms, target organs, first aid and measurement methods for covered workplace chemicals
US occupational-health guidance and limits; not a cosmetic ingredient decision
Rechercher cette identité à la sourceOECD eChemPortal
Gateway to authority-owned physical-property, fate, ecotoxicity, toxicity, exposure and GHS records
Discovery gateway; each linked authority remains responsible for its data
Rechercher cette identité à la sourceUS EPA CompTox CTX APIs
Clé d’API requise pour l’importDTXSID identity, experimental and predicted properties, toxicity, bioactivity, exposure and environmental data
Scientific and computational evidence; predictions must remain labelled and do not determine cosmetic legality
Rechercher cette identité à la source